AB1012 The efficacy and safety of ibandronate in patients with osteoporosis – importance of risk factors and fractures

Background Treatment of osteoporosis may be expected to affect the remodelling phase of bone repair and therefore promote fracture healing. Ibandronat significantly increase bone mineral density (BMD) and reduce the risk of vertebral, hip and non vertebral fractures in women with postmenopausal osteoporosis Objectives To confirm the efficacy and safety of 1 year ibandronate in OP pts: 150mg oral monthly or quarterly intravenously; to analyze the impact of risk factors and fractures on the efficacy of ibandronate treatment Methods 190 pts with primary OP,average 62.1y, average menopause 16.8y, treated 1 year with oral monthly or quarterly iv injection of ibandronate were included. BMD was measured by DXA Hologic at lumbar spine and proximal femur; OP is defined as the mean BMD expressed as a T-score = -5.0. The profil RTG of TH-LS spine was done before and after the therapy. Substitution of the optimal dose of vitamin D and calcium was applied. Results Previous fracture (37.6%)and smoking (33.5%) were the most common risk factors;75.1% pts had OP and more than one risk factor. Total number of vertebral and nonvertebral fractures at baseline was 71; 25 vertebral, 46 nonvertebral.After therapy, the number of new fractures was 18; 8 vertebral, 10 nonvertebral. After 1 year of oral monthly ibandronate BMD was increased at the spine for 3.0%,hip 3.5%,after ibandronate injection spine BMD was increased for 4.6%, hip 3.6%. Spine and hip BMD increase was higher in pts with OP and multiple risk factors (spine, p=0.000, hip, p=0.01)than those with one risk factor (spine, p=0.04; hip, p=0.02). Pts with multiple fractures and OP had a greater increase in spine and hipBMD(spine, p=0.000; hip, p=0.001) compared to those with 1 or without fracture (spine, p=0.04; hip, p=0.05). Pts with OP and previous BF treatment had no sign. BMD increase at the spine (p=0.334), nor on the hip (p=0.2)opposed to those not previously treated, with statistically sign. BMD increasing(spine, p=0.000, hip, p=0.006). Adverse events were rare,did not lead to stopped the treatment:7.8%pts had a flu like sy,1.1% LS pain,1.1% SVPT, stopped after medical therapy Conclusions Ibandronate is effective,safe drug, orally applied monthly or quarterly iv. in OP pts, especially those with multiple risk factors and multiple fractures Disclosure of Interest None Declared